Sarasin & Partners LLP Has $20.27 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Sarasin & Partners LLP grew its position in Edwards Lifesciences Co. (NYSE:EW) by 1.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 219,490 shares of the medical research company’s stock after purchasing an additional 3,104 shares during the period. Sarasin & Partners LLP’s holdings in Edwards Lifesciences were worth $20,274,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. DSM Capital Partners LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at about $28,000. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences in the 1st quarter worth approximately $28,000. First Community Trust NA bought a new stake in Edwards Lifesciences during the second quarter worth approximately $29,000. Riverview Trust Co acquired a new position in Edwards Lifesciences during the first quarter valued at approximately $34,000. Finally, Pingora Partners LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $38,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $4,108,777.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Bernard J. Zovighian sold 8,617 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the transaction, the chief executive officer now directly owns 68,218 shares of the company’s stock, valued at approximately $5,981,354.24. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total value of $437,700.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $4,108,777.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,242 shares of company stock valued at $2,498,870. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Trading Up 1.2 %

Shares of EW traded up $0.80 on Friday, reaching $68.92. 4,648,649 shares of the company’s stock were exchanged, compared to its average volume of 4,062,272. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market capitalization of $41.53 billion, a P/E ratio of 29.71, a price-to-earnings-growth ratio of 2.57 and a beta of 1.11. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The business has a 50 day moving average price of $80.76 and a two-hundred day moving average price of $85.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the previous year, the firm earned $0.66 earnings per share. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. Research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group lowered their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Truist Financial downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $110.00 to $82.00 in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft cut their price target on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, July 25th. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Finally, Stifel Nicolaus reduced their target price on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Fourteen research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.10.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.